$0.09 Earnings Per Share Expected for Meridian Bioscience, Inc. (NASDAQ:VIVO) This Quarter

Equities analysts predict that Meridian Bioscience, Inc. (NASDAQ:VIVO) will announce $0.09 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Meridian Bioscience’s earnings, with estimates ranging from $0.08 to $0.10. Meridian Bioscience posted earnings of $0.20 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 55%. The company is scheduled to announce its next earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Meridian Bioscience will report full-year earnings of $0.64 per share for the current fiscal year, with EPS estimates ranging from $0.63 to $0.65. For the next year, analysts expect that the business will post earnings of $0.51 per share, with EPS estimates ranging from $0.48 to $0.57. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.06. The business had revenue of $48.40 million for the quarter, compared to the consensus estimate of $49.81 million. Meridian Bioscience had a net margin of 12.65% and a return on equity of 17.82%. The firm’s quarterly revenue was down 6.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.18 EPS.

Several brokerages have weighed in on VIVO. Piper Jaffray Companies raised Meridian Bioscience from an “underweight” rating to a “neutral” rating and dropped their price objective for the stock from $15.00 to $11.00 in a report on Wednesday, May 1st. Canaccord Genuity reaffirmed a “sell” rating and issued a $9.00 price target on shares of Meridian Bioscience in a research note on Wednesday, July 31st. Zacks Investment Research cut Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Friday, July 5th. BidaskClub raised Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, ValuEngine raised Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Two research analysts have rated the stock with a sell rating and four have given a hold rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $13.25.

NASDAQ:VIVO traded down $0.28 on Monday, hitting $10.76. 131,200 shares of the stock were exchanged, compared to its average volume of 362,309. The firm has a market capitalization of $474.95 million, a PE ratio of 14.54 and a beta of 0.32. Meridian Bioscience has a 52 week low of $10.71 and a 52 week high of $19.84. The company has a quick ratio of 4.31, a current ratio of 6.93 and a debt-to-equity ratio of 0.40. The business has a 50-day moving average of $11.53.

In related news, Director James M. Anderson purchased 5,000 shares of the stock in a transaction dated Thursday, May 16th. The stock was bought at an average cost of $11.37 per share, with a total value of $56,850.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 2.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capital Fund Management S.A. bought a new stake in shares of Meridian Bioscience during the 2nd quarter valued at $138,000. Trexquant Investment LP bought a new stake in shares of Meridian Bioscience during the 2nd quarter valued at $141,000. Russell Investments Group Ltd. raised its stake in shares of Meridian Bioscience by 849.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 26,900 shares of the company’s stock valued at $315,000 after purchasing an additional 24,068 shares during the period. Verity Asset Management Inc. increased its stake in Meridian Bioscience by 15.1% in the 2nd quarter. Verity Asset Management Inc. now owns 27,338 shares of the company’s stock worth $435,000 after acquiring an additional 3,580 shares during the last quarter. Finally, Prudential Financial Inc. increased its stake in Meridian Bioscience by 4.1% in the 2nd quarter. Prudential Financial Inc. now owns 84,224 shares of the company’s stock worth $1,001,000 after acquiring an additional 3,339 shares during the last quarter. 89.79% of the stock is owned by institutional investors.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Recommended Story: What Does a Sell-Side Analyst Rating Mean?

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit